Page last updated at 07:35 GMT, Wednesday, 3 February 2010

Tamiflu sales boost Roche profits

Tamiflu sales helped boost profits but are set to fall sharply in 2010

Swiss drugs firm Roche has reported an 8% rise in annual sales, helped by sales of swine flu drug Tamiflu and cancer treatments, such as Herceptin.

The rate of growth is twice the industry average and operating profits were up by 14% to 15bn Swiss francs ($14.2bn, £8.89bn).

However, overall net income for the year fell 22% to 8.5bn Swiss francs as a result of takeover costs.

Last year, Roche bought US pharmaceutical giant Genentech.

It says that this deal is already proving profitable.

Although sales of Tamiflu soared last year, they are expected to fall sharply in 2010, to 1.2bn Swiss francs from 3.2bn Swiss francs in 2009.

Print Sponsor

Flu treatment output 'to triple'
22 Jul 09 |  Business
Roche seals $47bn Genentech deal
12 Mar 09 |  Business

The BBC is not responsible for the content of external internet sites

Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit


Sign in

BBC navigation

Copyright © 2019 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific